Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02573233 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

A Phase 2 study of Asthma, sponsored by Sanofi.

Completed
Registry status
Phase 2
Development phase
42
Enrollment target
16
Study locations

NCT02573233 is a Phase 2 study of Asthma that has completed, run by Sanofi. The registered enrollment target is 42 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02573233, a Phase 2 study of Asthma, has completed, sponsored by Sanofi.

COMPLETED
Registry status
Phase 2
Development phase
42 participants
Enrollment target
16
Study locations

Study Summary

Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo
  • DRUG Dupilumab SAR231893/REGN668
  • DRUG fluticasone propionate and salmeterol
  • DRUG budesonide and formoterol
  • DRUG mometasone furoate and formoterol

Study Locations (16)

Other

  • Investigational Site Number 124012 - Montreal
  • Investigational Site Number 124018 - Sainte-Foy
  • Investigational Site Number 208002 - Hvidovre
  • Investigational Site Number 208001 - København NV
  • Investigational Site Number 276013 - Frankfurt am Main
  • Investigational Site Number 276011 - Großhansdorf
  • Investigational Site Number 276012 - Hanover
  • Investigational Site Number 752001 - Lund
  • Investigational Site Number 826010 - London
  • Investigational Site Number 826009 - Oxford

Arizona

  • Investigational Site Number 840402 - Tucson

Colorado

  • Investigational Site Number 840403 - Denver

Massachusetts

  • Investigational Site Number 840401 - Boston

Missouri

  • Investigational Site Number 840002 - St Louis

North Carolina

  • Investigational Site Number 840404 - Winston-Salem

Pennsylvania

  • Investigational Site Number 840028 - Pittsburgh

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2016-01-27
Est. Completion 2018-01-03
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02573233

The ClinicalTrials.gov registry entry for NCT02573233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT02573233 reports 16 study locations spanning 7 distinct geographic areas - top geographies include Other, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT02573233 about?

NCT02573233 is a clinical study titled "Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma". Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.

What is the current status of trial NCT02573233?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-01-27. Estimated completion is 2018-01-03.

What conditions does trial NCT02573233 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT02573233?

The interventions under investigation include: Placebo (DRUG), Dupilumab SAR231893/REGN668 (DRUG), fluticasone propionate and salmeterol (DRUG), budesonide and formoterol (DRUG), mometasone furoate and formoterol (DRUG).

Who is sponsoring clinical trial NCT02573233?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02573233 being conducted?

This trial has 16 study locations across Arizona, Colorado, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.